The effect of blood pressure and cholesterol variability on the precision of Framingham cardiovascular risk estimation: A simulation study

Journal of Human Hypertension

Volumn 24, Issue 10, 2010, Pages 631-638

  Marshall, T ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

coronary heart disease; diagnosis; measurement error; primary care; risk stratification; screening

Indexed keywords

HIGH DENSITY LIPOPROTEIN;

ADULT; AGE; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONFIDENCE INTERVAL; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALIDITY; PROBABILITY; SYSTOLIC BLOOD PRESSURE;

ADULT; AGE FACTORS; AGED; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL; COMPUTER SIMULATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, CARDIOVASCULAR; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS;

EID: 77956879328     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2009.114     Document Type: Article

References (24)

1. Jackson R, Barham P, Maling T, MacMahon S, Bills J, Birch B et al. The management of raised blood pressure in New Zealand. Br Med J 1993; 307: 107-110.
2. Anderson KM, Odell PM, Silson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1990; 121: 293-298.
3. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139-185.
4. Developed by the Newcastle Guideline Development and Research Unit. Hypertension: Management of Hypertension in Adults in Primary Care. NICE: London, 2004.
5. Cooper A, Nherera L, Calvert N, O'Flynn N, Turnbull N, Robson J et al. Clinical Guidelines and Evidence Review for Lipid Modification: Cardiovascular Risk Assessment and the Primary and Secondary Prevention of Cardiovascular Disease. National Collaborating Centre for Primary Care and Royal College of General Practitioners: London, 2008.
6. Scottish Intercollegiate Guidelines Network Risk estimation and the prevention of cardiovascular disease. A national clinical guideline. Scottish Intercollegiate Guidelines Network, Edinburgh: SIGN; 2007 (SIGN Guideline no. 97) Available from url: http:// www.sign.ax.uk.
7. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S,Menotti A, De Backer G, et al., on behalf of the SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003.
8. De Backer G, Ambrosioni E, Borch-Johnsena K, Brotonsh C, Cifkovae R, Dallongevillee J et al. Executive Summary: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2003; 10: S1-S10.
9. Thomsen TF, DavidsenM, Ibsen H, Jorgensen T, Jensen G, Borch-Johnsen K. A new method for CHD prediction and prevention based on regional risk scores and randomized clinical trials; PRECARD and the Copenhagen Risk Score. J Cardiovas Risk 2001; 8(5): 291-297.
10. Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to the cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 2007; 2: 172-176.
11. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. Br Med J 2008; 336: a332.
12. Rosner B, Polk BF. The implications of blood pressure variability for clinical and screening purposes. J Chron Dis 1979; 32(6): 451-461.
13. Department of Health. Health Survey for England 1998 (http://www.data- archive.ac.uk/) (accessed on 25 May 2005).
14. Keenan K, Hayen A, Neal BC, Irwig L. Long term monitoring in patients receiving treatment to lower blood pressure: analysis of data from placebo controlled randomised controlled trial. Br Med J 2009; 338: b1492 (Published online 30 April 2009).
15. Ortola J, Castineiras MJ, Fuentes-Arderiu X. Biological variation data applied to the selection of serum lipid ratios used as risk markers of coronary heart disease. Clin Chem 1992; 38(1): 56-59.
16. Department of Health. Health Survey for England 2003 (http://www.data- archive.ac.uk/) (accessed on 25 May 2005).
17. Gordon T, Sorlie P, Kannel WB. Problems in the assessment of blood pressure: the Framingham Study. Int J Epidemiol 1976; 5(4): 327-334.
18. Reynolds TM, Twomey P, Wierzbicki AS. Accuracy of cardiovascular risk estimation for primary prevention in patients without diabetes. J Cardiovasc Risk 2002; 9(4): 183-190.
19. Wright JM, Musini VJ. Blood pressure variability: lessons learned from a systematic review. Poster presentation D20, 8th International Cochrane Colloquium, October 2000, Cape Town.
20. Bryan S, Gill P, Greenfield S, Gutridge K, Marshall T. Predictors of patients' preferences for treatments to prevent heart disease. Heart 2006; 92: 1651-1655.
21. Lumley T, Rice KM, Psaty BM. Carryover effects after cessation of drug treatment: trophies or dreams? Am J Hypertens 2008; 21: 85-91.
22. Turner MJ, Van Schalkwyk JM. Blood pressure variability causes spurious identification of hypertension in clinical studies-a computer simulation study. Am J Hypertens 2008; 21: 14-16.
23. Department of Health. Putting Prevention First. Vascular Checks: Risk Assessment and Management Department of Health: London 2008, available online: http://www.dh.gov.uk/en/Publicationsandstatistics/ Publications/ PublicationsPolicyAndGuidance/DH- 083822.
24. Marshall T, Westerby P, Chen J, Fairfield M, Harding J, Westerby R et al. The Sandwell Project: a controlled evaluation of a programme of targeted screening for prevention of cardiovascular disease in primary care. BMC Public Health 2008; 8: 73.